Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | SLC25A20 | O43772 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.76 |
| ▸ | GMNN | O75496 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palmitoyl-Carnitine SCHEMBL116634 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL19182624 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL187668 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL188359 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL855471 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL8067110 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL25373354 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL1958560 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL198686 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL115183 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 908 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260120870-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | INNOBATION BIO CO LTD (KR) | 2026-04-30 | — | — | US | claimed |
| US-12493041-B2 | Apparatus for diagnosing solid cancers and method for providing information on solid cancer diagnosis | INNOBATION BIO CO., LTD. (KR) | 2025-12-09 | — | — | US | claimed |
| EP-4597111-A1 | USE OF METABOLIC MARKER FOR DIAGNOSIS OF LUNG CANCER STAGING AND KIT | Harbin Metanotitia Inc. (CN) | 2025-08-06 | — | — | EP | claimed |
| EP-4597100-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | Innobation Bio Co., Ltd. (KR) | 2025-08-06 | — | — | EP | claimed |
| US-12370173-B2 | Pet food compositions that modulate vitamin D and bone mineral content in a companion animal | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-07-29 | — | — | US | claimed |
| CN-120089347-A | Neonate genetic metabolism disease screening automatic interpretation system based on artificial intelligence | 洛阳瀚纳生物科技有限公司 | 2025-06-03 | — | — | CN | claimed |
| US-12320798-B2 | Diagnostic methods, therapeutic agents and uses thereof | METABOLON, INC. (US) | 2025-06-03 | — | — | US | claimed |
| US-12292445-B2 | Methods of selecting subjects for treatment with metabolomic modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-06 | — | — | US | claimed |
| CN-119564888-A | Technetium [99Tc (Tc) methylene bisphosphonate oral preparation, preparation method and application thereof | 成都云克药业有限责任公司 | 2025-03-07 | — | — | CN | claimed |
| US-20250003930-A1 | METHOD FOR ANALYZING AMINO ACIDS AND/OR ACYLCARNITINES | SHIMADZU CORPORATION (JP) | 2025-01-02 | — | — | US | claimed |
| EP-0845265-A1 | MUCOSAL PREPARATION CONTAINING PHYSIOLOGICALLY ACTIVE PEPTIDE | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-06-03 | — | — | EP | claimed |
| US-5316917-A | Automated analysis of free l-carnitine and total short-chain acylcarnitine | DUKE UNIVERSITY (US) | 1994-05-31 | — | — | US | claimed |
| EP-0215697-B1 | ACYLCARNITINES AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL COMPARTMENTS | MERCK & CO. INC. (US) | 1992-03-25 | — | — | EP | claimed |
| US-4963525-A | POLYPEPTIDES | MERCK & CO., INC. (US) | 1990-10-16 | — | — | US | claimed |
| EP-0162764-B1 | COMPOSITION AND METHOD FOR ENHANCING ABSORPTION OF DRUGS FROM GASTROINTESTINAL TRACT USING ACYLCARNITINES | MERCK & CO. INC. (US) | 1989-08-09 | — | — | EP | claimed |
| US-4847298-A | DOPA COMPOUNDS OR ANTIBIOTICS | MERCK & CO., INC. (US) | 1989-07-11 | — | — | US | claimed |
| US-4731360-A | Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments | MERCK & CO., INC. (US) | 1988-03-15 | — | — | US | claimed |
| EP-0215697-A2 | Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments | MERCK & CO. INC. (US) | 1987-03-25 | — | — | EP | claimed |
| EP-0162764-A1 | Composition and method for enhancing absorption of drugs from gastrointestinal tract using acylcarnitines | MERCK & CO. INC. (US) | 1985-11-27 | — | — | EP | claimed |
| US-4537772-A | Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines | MERCK & CO., INC. (US) | 1985-08-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370173-B2 | Pet food compositions that modulate vitamin D and bone mineral content in a companion animal | CYP24A1, GC, VDR | MAPT 1332/4885MEN1 165/4885KMT2A 3472/4885 |
| US-20260120870-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | KYNU, CPT2, CPT1A | MAPT 4480/4885MEN1 1628/4885KMT2A 564/4885 |
| US-12320798-B2 | Diagnostic methods, therapeutic agents and uses thereof | INSR, IAPP, GPR119 | MAPT 2773/4885MEN1 348/4885KMT2A 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.